Buprenorphine is used in opioid dependence treatment primarily because:

• A It is a full agonist at mu-opioid receptors with very high potency
• B It has short half-life allowing dose titration to avoid withdrawal
• C It undergoes complete renal excretion without hepatic metabolism
• D It is a partial mu-agonist and kappa-antagonist with a ceiling effect on respiratory depression and high receptor affinity that blocks euphoric effects of other opioids ✓

Explanation

Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors. As a partial agonist, it produces submaximal opioid effects even at full receptor occupancy (ceiling effect on euphoria and respiratory depression), enhancing safety. Its extremely high receptor affinity (slow receptor dissociation, t½ displacement ~24 h) means it competitively displaces full agonists, blocking their euphoric effects — the basis for addiction maintenance therapy. Its long half-life (~24-60 h) also allows once-daily or every-other-day dosing.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.